If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]
GeNeuro (Euronext Paris: CH0308403085 — GNRO), a biopharmaceutical company that develops new treatments against neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the serious consequences of COVID-19 (post-COVID or COVID long), announces today its half-year results for the period ended June 30, 2022 and provides an update on its developments.
On September 29, 2022, GeNeuro’s Board of Directors reviewed and approved the financial statements for the six-month period ended June 30, 2022. The statutory auditors reviewed the condensed consolidated half-year financial statements. The half-year financial report (in English) is available in the Investors section of the www.geneuro.com website.